{"name":"CSL Limited","slug":"csl-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"IgNextGen 16%","genericName":"IgNextGen 16%","slug":"ignextgen-16","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"Ig NextGen 10%","genericName":"Ig NextGen 10%","slug":"ig-nextgen-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IgNextGen 10%","genericName":"IgNextGen 10%","slug":"ignextgen-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IntragamP","genericName":"IntragamP","slug":"intragamp","indication":"Primary immunodeficiency disorders","status":"phase_3"}]}],"pipeline":[{"name":"IgNextGen 16%","genericName":"IgNextGen 16%","slug":"ignextgen-16","phase":"phase_3","mechanism":"IgNextGen 16% is an intravenous immunoglobulin (IVIG) product that provides passive immunization by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions"],"catalyst":""},{"name":"Ig NextGen 10%","genericName":"Ig NextGen 10%","slug":"ig-nextgen-10","phase":"phase_3","mechanism":"Ig NextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions","Autoimmune and inflammatory disorders (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"IgNextGen 10%","genericName":"IgNextGen 10%","slug":"ignextgen-10","phase":"phase_3","mechanism":"IgNextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"IntragamP","genericName":"IntragamP","slug":"intragamp","phase":"phase_3","mechanism":"IntragamP is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.","indications":["Primary immunodeficiency disorders","Autoimmune and inflammatory conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVEk5NFMxTk8tWGhlT0tBTHg5cnhGLUVYeF9TZEY2M0kyMDg0SXBJemdQME1TTDhpeldsT2tCclFoejJ1Y2hEWnFiZnBfaWJCMVVFQmV2NkdxcmY0X1FSY3VUbFlGWlNDY3Boakkza0NhVm1TTWxjdTZDNjExemF0N3ZZZHhxdXB4dnVQeHlkcnp0YjJCODl6MS1ZOTl1anJyVzcwOENCQWY?oc=5","date":"2026-04-07","type":"pipeline","source":"Kalkine Media","summary":"ASX 20: What US tariffs mean for CSL and Mayne Pharma shares - Kalkine Media","headline":"ASX 20: What US tariffs mean for CSL and Mayne Pharma shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNVHByZnlSdFZ4QmN2YXg2QUhHQjBMX3VHVXVMUmFVWTBEaTNwenlJcTFKYU1qWjhFVVZjd3NyclpxbGowNVpUSmJUTUplY3h4ZG0wVVowV1o3YkVkeDBjVGQwMVI0MnQ5aWlFSU81ZVM4UjFVSm9BV0h3Y2JfSWl2NWU1N05WX1p5bWYxbGl6V0FTZUZfQ18wVWRta0pFTjM2OEkxeldMbjNVWlRpVm1RcjV5N2hxZw?oc=5","date":"2026-04-07","type":"pipeline","source":"PharmaDispatch","summary":"Australian companies downplay US tariff risk as CSL and Mayne signal limited impact - PharmaDispatch","headline":"Australian companies downplay US tariff risk as CSL and Mayne signal limited impact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNa0lNZ3hYczZjVVpKOGRqN0tEdUJqMUozUXZMNzVOUzZPY2tYUkJLVkxLdmZ5V1ROZkwwdVJsM0hwYXZpVkptS2lJQ1hEN2dybFZiNEx3dlphSk5UQ2QxVHFmSUlzZFlGNW5zWFEzcHNwQUNadWFldVBtbGNJSDZDLWZjU1lXSDdhMW9sakplekQ2dkVRcUxvWXRR?oc=5","date":"2026-03-20","type":"pipeline","source":"Kalkine Media","summary":"Is ASX 200 CSL Expansion Reshaping Pharma Sector? - Kalkine Media","headline":"Is ASX 200 CSL Expansion Reshaping Pharma Sector?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcTNuaGZUVFk1U000cWZrZE5iZVhYZ3JmTkdXLVU3blFZQUlKN0NHQWNTczZZQ2lIODMzWE13VzNSOWZzSGRnSGhfNlc1LXNhcjNfTVNQZVYxajJLcmQ3Wnc5WEN1NFBaS01XLUFtTm5DYWZVTWdHVkVvWHN3ZU1zSU9aQmVtVm5LTjNUX1hEb0cxZDQ3dVNHUElNUzhiR3ZxdUF1dnZDajc?oc=5","date":"2026-02-18","type":"deal","source":"BioPharma Dive","summary":"Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6 - BioPharma Dive","headline":"Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQaEtkcTRKTWMydmtESGJaWWlvWUNaYk1wdDNvT25CWWY0cGtPUnhJdlU2U1kxekd0Nm4ySi1TdnBweFhZbHB3WTdKNUp6Z1pPdWJmZ1R6NlRjRDdNMFFvVlJndk5fVGtCakd0allaZ3ZoNEtmNUxFUGkyaFhQN01KQjhvOHlERDFGUTBVTFVYWVU0UnI0Z3VjZmMwVlV2UFB0SF9vQQ?oc=5","date":"2026-02-18","type":"pipeline","source":"MedCity News","summary":"Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug - MedCity News","headline":"Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNbVJRc3pyZG54MGRlRko1RjRJUWZzUDh3N3JBNGQwZjhITDBBb2NSRDBwd2N5X3lIb1NjQ3M2X2wwNDFpNFRPaGgzVnpJM3pmeVZTTDllcExrc0xzdWlpOFIzcW5kTVI0ZEpiMGJFQmNNZXJmSHg4clFMZ2tVQzBkNFRsVVJiSEJrN1BPcVBtQkQ5SllpMTZVSW9ndEx5TVdna0xZ?oc=5","date":"2026-02-18","type":"pipeline","source":"The Pharma Letter","summary":"CSL and Lilly enter licensing agreement for clazakizumab - The Pharma Letter","headline":"CSL and Lilly enter licensing agreement for clazakizumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNY1hxbks4dHpxUThfeHBmX3czcTk1dXhDYktzSS15STMybzVCSzRHa21UU3prLVhQZVBtZ3UySXpzelEyMGNseEtWMHZxTFlVY0xOUV9sNi1ld3N5X1diNVVfalgxRDJucWRVY1BvS2ZiVDFUc1FZaG9ubURHcFR0eG9lTnBfU0Z4dlZ5WW1oWWNYMWFGTWFPSERFNC0wUHJBamJjQXlR?oc=5","date":"2026-02-16","type":"pipeline","source":"SWI swissinfo.ch","summary":"Pharma company CSL Behring plans Swiss job cuts - SWI swissinfo.ch","headline":"Pharma company CSL Behring plans Swiss job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOcUpvaFoxekRpdkQ5T05VUi1XNnNXUndnMW9zaGNxQXBfaVp5YVBIS2h1MEtDakN3NXVKbjdfZkplSk10ZGJqUTRvUTdYYjV4aUFOTDNyV2tVUTdvV3hTNDM5ejZLekQ4bjUwVlpfWWhhbHJkNThuRWotaFgtUEUtejgxRFRUalVYY0ZKdlJzR0lWRzlDeURV?oc=5","date":"2026-02-11","type":"pipeline","source":"The Pharma Letter","summary":"Change at the top aimed at ending CSL struggles - The Pharma Letter","headline":"Change at the top aimed at ending CSL struggles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQNE1SbEZHNVlPdmdDOXRfQWFlSjZRZzZrRTJHMjh4Snl5TnNPVGRUNzhXSWtvMTcwYnViV2FVdmg0WmFPdDdrYjY4WThjTE9mRGN6TFZLa0p6dGVwaGwxdTE5ampMeGV2eWV0R2pSaFZvdUptSU1YX3RaRUthRWxwdHh3WGZsaTVCZjZWSUpNV0hadlEtMnNDSmVIY1pFSXhTVmx5NXlFOA?oc=5","date":"2026-02-05","type":"pipeline","source":"Stockhead","summary":"January Health Winners: CSL drives index gains in month of mixed results - Stockhead","headline":"January Health Winners: CSL drives index gains in month of mixed results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxORl9pVDBTQTZuMWlhZFZjR0FuNDN1OElIMlNNNEpfOXJ5dlhkSlJ3eW4wV2xkUS1RTXNKNHZpT240ajFraFpJUlBRQTk3OG5ia3kwck0wODR4SWZaVVNQVmlQOUpwQS1GNktrNnJHRnluWkNhVk5BVHRFLWhhWW1sdG40THdGT0RKbmQ5RVE4X1dqTVVjTTBXcHdoUEZaSHVyd09rdkdKWFVOSHl4Z0hMWS1mWlJOREk?oc=5","date":"2025-11-18","type":"pipeline","source":"The Pharma Letter","summary":"CSL to invest $1.5 billion in USA to manufacture plasma-derived therapies - The Pharma Letter","headline":"CSL to invest $1.5 billion in USA to manufacture plasma-derived therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOU0VsbGhNUUpUNTJrdDJLbVJoejNpVnJPQndDVlJzSmhfZ0ZRaENIQk5GS2JDX0pUVTRxNWRBd2p2a1AwT0UxVUhwU3ExR0FQRm13a1g4Q3RSaVR1eWN0NWhNZGhmOTEzd0VHdTE1eXdzdnlBbmZIbFlVNVpiN2pOSjRZYWJxQnAzRXd3NXA2QVhIRS03cG9OdU5yYkNVdXFBNmdfb25aUkNDcnFDTWhLaVFua2xJOHA3TnpOaExZblBtWm9YeTZaZ2FDbk1xMjBFQUJYdDZxVjd5YUVfUHJQMktra0dUdkt6RnlJQzF3?oc=5","date":"2025-10-26","type":"pipeline","source":"Investing News Network","summary":"CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering - Investing News Network","headline":"CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNUJTbURUdGh4amV2QU9kUDZCaEtXOEtFU1B5OWM5UVNBOFJCbU9qSjVpWXZfWVVXb2lLaVlYRWxTTm5YS0gzMEszUzg0U3BTa05EU1F4MTdCTkQ5Nl9senU0SHUwMk9SUURFZmxTUW1GZHp2SmZlQ1UxR1ZGWnc0VUNzRTdIQ1Qxb2l2SmFaZENDREU1bFFlY1Y5NFB6Z055TUpzV25uQ0tHUjZkbElRMmtzT1NCZE9kbFVXbXE3ZEs?oc=5","date":"2025-10-02","type":"pipeline","source":"AFR","summary":"CSL exposed as industry moves to avoid tariffs - AFR","headline":"CSL exposed as industry moves to avoid tariffs","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}